172 related articles for article (PubMed ID: 21398295)
1. Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C.
Macías J; Neukam K; Portilla J; Iribarren JA; de Los Santos I; Rivero A; Márquez M; Delgado M; Téllez F; Merino D; Giner L; von Wichmann MA; Pineda JA;
J Antimicrob Chemother; 2011 Jun; 66(6):1346-50. PubMed ID: 21398295
[TBL] [Abstract][Full Text] [Related]
2. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.
Vispo E; Mena A; Maida I; Blanco F; Cordoba M; Labarga P; Rodriguez-Novoa S; Alvarez E; Jimenez-Nacher I; Soriano V
J Antimicrob Chemother; 2010 Mar; 65(3):543-7. PubMed ID: 20032006
[TBL] [Abstract][Full Text] [Related]
3. Creatine kinase elevation in HIV-1-infected patients receiving raltegravir-containing antiretroviral therapy: a cohort study.
Monteiro P; Perez I; Pich J; Gatell JM; Martínez E
J Antimicrob Chemother; 2013 Feb; 68(2):404-8. PubMed ID: 23109185
[TBL] [Abstract][Full Text] [Related]
4. Highly active antiretroviral therapy-related hepatotoxicity in human immunodeficiency virus and hepatitis C virus co-infected patients with advanced liver fibrosis in Taiwan.
Chou CC; Tsai HC; Wu KS; Sy CL; Chen JK; Chen YS; Lee SS
J Microbiol Immunol Infect; 2016 Aug; 49(4):546-53. PubMed ID: 25440980
[TBL] [Abstract][Full Text] [Related]
5. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.
Macías J; Mira JA; López-Cortés LF; Santos I; Girón-González JA; González-Serrano M; Merino D; Hernández-Quero J; Rivero A; Merchante N; Trastoy M; Carrillo-Gómez R; Arizcorreta-Yarza A; Gómez-Mateos J; Pineda JA
Antivir Ther; 2006; 11(7):839-46. PubMed ID: 17302246
[TBL] [Abstract][Full Text] [Related]
6. Favourable one-year ART outcomes in adult Malawians with hepatitis B and C co-infection.
Moore E; Beadsworth MB; Chaponda M; Mhango B; Faragher B; Njala J; Hofland HW; Davies J; Hart IJ; Beeching NJ; Zijlstra EE; van Oosterhout JJ
J Infect; 2010 Jul; 61(2):155-63. PubMed ID: 20470823
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus viral recurrence and liver mitochondrial damage after liver transplantation in HIV-HCV co-infected patients.
Duclos-Vallée JC; Vittecoq D; Teicher E; Feray C; Roque-Afonso AM; Lombès A; Jardel C; Gigou M; Dussaix E; Sebagh M; Guettier C; Azoulay D; Adam R; Ichaï P; Saliba F; Roche B; Castaing D; Bismuth H; Samuel D
J Hepatol; 2005 Mar; 42(3):341-9. PubMed ID: 15710216
[TBL] [Abstract][Full Text] [Related]
8. The prevalence and risk of hepatitis flares in a Serbian cohort of HIV and HCV co-infected patients treated with HAART.
Jevtović Dj; Ranin J; Salemović D; Pesić I; Dragović G; Zerjav S; Djurković-Djaković O
Biomed Pharmacother; 2008 Jan; 62(1):21-5. PubMed ID: 17223307
[TBL] [Abstract][Full Text] [Related]
9. Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?
Cicconi P; Cozzi-Lepri A; Phillips A; Puoti M; Antonucci G; Manconi PE; Tositti G; Colangeli V; Lichtner M; Monforte Ad;
AIDS; 2007 Mar; 21(5):599-606. PubMed ID: 17314522
[TBL] [Abstract][Full Text] [Related]
10. Liver ultrastructural morphology and mitochondrial DNA levels in HIV/hepatitis C virus coinfection: no evidence of mitochondrial damage with highly active antiretroviral therapy.
Matsukura M; Chu FF; Au M; Lu H; Chen J; Rietkerk S; Barrios R; Farley JD; Montaner JS; Montessori VC; Walker DC; Côté HC
AIDS; 2008 Jun; 22(10):1226-9. PubMed ID: 18525271
[TBL] [Abstract][Full Text] [Related]
11. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus.
Martinez-Sierra C; Arizcorreta A; Díaz F; Roldán R; Martín-Herrera L; Pérez-Guzmán E; Girón-González JA
Clin Infect Dis; 2003 Feb; 36(4):491-8. PubMed ID: 12567308
[TBL] [Abstract][Full Text] [Related]
12. HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension.
Reiberger T; Ferlitsch A; Sieghart W; Kreil A; Breitenecker F; Rieger A; Schmied B; Gangl A; Peck-Radosavljevic M
J Viral Hepat; 2010 Jun; 17(6):400-9. PubMed ID: 19780945
[TBL] [Abstract][Full Text] [Related]
13. Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients.
Torti C; Lapadula G; Uccelli MC; Quiros-Roldan E; Regazzi M; Ladisa N; Micheli V; Orani A; Patroni A; Caputo SL; Tirelli V; Di Giambenedetto S; Cologni G; Costarelli S; Gargiulo F; Manca N; Carosi G;
Int J Antimicrob Agents; 2007 Feb; 29(2):185-90. PubMed ID: 17011754
[TBL] [Abstract][Full Text] [Related]
14. Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy.
Tuma P; Medrano J; Resino S; Vispo E; Madejón A; Sánchez-Piedra C; Rivas P; Labarga P; Martín-Carbonero L; Barreiro P; Soriano V
Antivir Ther; 2010; 15(6):881-6. PubMed ID: 20834100
[TBL] [Abstract][Full Text] [Related]
15. Grade 3-4 liver enzyme elevation during HAART in HIV and hepatitis C co-infected adults.
Yunihastuti E; Gani RA; Lesmana LA; Sundaru H; Djauzi S
Acta Med Indones; 2009 Jul; 41(3):130-5. PubMed ID: 19752485
[TBL] [Abstract][Full Text] [Related]
16. Response to Cicconi et al. 'Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?'.
Núñez M
AIDS; 2007 Jul; 21(12):1660. PubMed ID: 17630570
[No Abstract] [Full Text] [Related]
17. Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database.
Petoumenos K; Ringland C;
HIV Med; 2005 May; 6(3):155-63. PubMed ID: 15876281
[TBL] [Abstract][Full Text] [Related]
18. Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients.
Cordery DV; Hesse K; Amin J; Cooper DA
Antivir Ther; 2010; 15(7):1035-8. PubMed ID: 21041919
[TBL] [Abstract][Full Text] [Related]
19. [Chronic hepatitis C in HIV-infected patients receiving highly active antiretroviral therapy (HAART)].
Halota W; Pawłowska M
Przegl Epidemiol; 2002; 56 Suppl 5():41-5. PubMed ID: 15553071
[TBL] [Abstract][Full Text] [Related]
20. Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.
Pineda JA; Santos J; Rivero A; Abdel-Kader L; Palacios R; Camacho A; Lozano F; Macías J;
J Antimicrob Chemother; 2008 Apr; 61(4):925-32. PubMed ID: 18276600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
